Compare VanEck Australian Floating Rate ETF (FLOT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs IDEXX Laboratories, Inc. — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.6× VanEck Australian Floating Rate ETF's market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FLOT | IDXX | |
|---|---|---|
Market Cap | $11.24B | $40.43B |
Volume | 1,872,962 | 692,164 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $766.68 |
52-Week Low | $50.72 | $504.70 |
Typical Hold Time | 21 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.96 with minimal daily movement (+0.1%) amid bearish technical signals. The ETF faces concentration risk with 47% bank exposure while benefiting from floating rate exposure during Fed tightening cycles. Recent dividend payments of $0.17-0.18 reflect current yield environment, though technical indicators show strong selling pressure with moving averages and ADX signaling bearish momentum.
The floating rate structure positions FLOT to benefit from continued Fed hawkishness, but high bank concentration presents sector-specific risks. Current technical weakness suggests near-term pressure, while the fund's yield advantage over cash equivalents remains attractive for income-focused investors in rising rate environments.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
